Loading...
•
Jun 30, 2020
Anika Q2 2020 Earnings Report
Anika increased total revenue year-over-year for the quarter and accelerated the commercial integration of Parcus Medical and Arthrosurface organizations.
Key Takeaways
Anika Therapeutics reported a 1% year-over-year increase in total revenue to $30.7 million for the second quarter of 2020. The company is integrating Parcus Medical and Arthrosurface and launching seven FDA-cleared products through Q3 2020.
Total revenue increased 1% year-over-year to $30.7 million.
Commercial integration of Parcus Medical and Arthrosurface organizations was accelerated.
Seven FDA-cleared orthopedic and sports medicine products are launching through Q3 2020.
The company is focused on managing costs and maintaining a strong balance sheet during the COVID-19 pandemic.